Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients
about
An epigenetic master regulator teams up to become an epioncogene.DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
P2860
Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Promoter methylation of MCAM, ...... stage prostate cancer patients
@en
Promoter methylation of MCAM, ...... stage prostate cancer patients
@nl
type
label
Promoter methylation of MCAM, ...... stage prostate cancer patients
@en
Promoter methylation of MCAM, ...... stage prostate cancer patients
@nl
prefLabel
Promoter methylation of MCAM, ...... stage prostate cancer patients
@en
Promoter methylation of MCAM, ...... stage prostate cancer patients
@nl
P2093
P2860
P356
P1433
P1476
Promoter methylation of MCAM, ...... stage prostate cancer patients
@en
P2093
Akira Ooki
Alan Partin
David Sidransky
Eli Rosenbaum
Elisa Guida
Elizabeth Humphreys
Evgeny Izumchenko
Leonel Maldonado
Leslie Mangold
Mithu Banerjee
P2860
P304
15431-15440
P356
10.18632/ONCOTARGET.14873
P407
P577
2017-02-01T00:00:00Z